Avibactam sodium CAS:1192491-61-4

Avibactam sodium is utilized in clinical practice as a beta-lactamase inhibitor to restore the efficacy of certain antibiotics against multidrug-resistant bacteria. It is commonly combined with antibiotics such as ceftazidime to create fixed-dose combinations that target a broad spectrum of Gram-negative pathogens, including Enterobacteriaceae and Pseudomonas aeruginosa. Healthcare providers prescribe avibactam sodium-containing antibiotics for complicated intra-abdominal infections, urinary tract infections, hospital-acquired pneumonia, and other serious bacterial infections caused by organisms resistant to standard antibiotics. The addition of avibactam sodium helps overcome bacterial resistance mechanisms, restoring the effectiveness of the antibiotics in combating difficult-to-treat infections. Dosage regimens incorporating avibactam sodium are tailored based on the specific infection, patient factors, susceptibility testing results, and the antibiotic combination used. Close monitoring of treatment response, microbial susceptibility patterns, and potential adverse effects is essential to ensure optimal therapeutic outcomes and minimize the risk of treatment failure. Adverse effects associated with avibactam sodium-containing antibiotics may include gastrointestinal disturbances, hypersensitivity reactions, and risks related to concomitant antibiotic use. Healthcare providers must consider individual patient characteristics and medication interactions when prescribing these combinations to optimize treatment efficacy and safety. By combining avibactam sodium with appropriate antibiotics, healthcare professionals can effectively address challenging multidrug-resistant bacterial infections, offering patients alternative treatment options and improving clinical outcomes in the management of complex infectious diseases.